Halozyme (HALO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$110.19-0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HALO
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $110 HALO trades at 23× p/e, in line with its 22× p/e peer median, and our $118 fair value agrees. We hold it with medium confidence: quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Analysts target $90–$115. Note: our $118 fair value sits above the entire analyst range ($90–$115). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $100.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $265.64 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $315.05 | — | — | Hist. CAGR | high |
| graham number | 12M | $11.39 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$90.00 – $115.00 (median $100.00) · 6 analysts · as of 2026-08-10
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $102.62 |
| 15.9 |
| 7.48 |
| TTM |
| high |
| Peer P/FCF | 12M | $143.57 | 21.6 | 6.65 | TTM | high |
| Peer P/E | 12M | $175.53 | 18.1 | 9.69 | ntm analyst | high |
| Peer P/S | 12M | $156.22 | 11.4 | 13.73 | TTM | high |
| PEG | 12M | $67.45 | 13.8 | 4.87 | TTM | high |
| residual income | 12M | $19.48 | — | — | TTM | high |
| triangulated | 12M | $112.59 | 22.0 | 5.12 | Triangulated | high |
| Peer P/FCF | 3Y | $218.35 | 21.6 | 10.12 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $97.76 | 18.1 | 5.40 | Analyst | medium |
| Peer P/S | 3Y | $100.90 | 11.4 | 8.86 | guidance | medium |
| PEG | 3Y | $74.73 | 13.8 | 5.40 | Analyst | medium |
| Peer P/FCF | 5Y | $288.77 | 21.6 | 13.38 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $46.71 | 18.1 | 2.58 | Analyst | medium |
| Peer P/S | 5Y | $48.21 | 11.4 | 4.24 | guidance | medium |
| PEG | 5Y | $35.70 | 13.8 | 2.58 | Analyst | medium |